Trial record 2 of 58 for:    Inclusion Body Myositis

Study of Arimoclomol in Inclusion Body Myositis (IBM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02753530
Recruitment Status : Recruiting
First Posted : April 28, 2016
Last Update Posted : December 7, 2018
University of Kansas Medical Center
University College, London
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2021
  Estimated Study Completion Date : December 2021